Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.92 USD
Change Today +0.0301 / 3.38%
Volume 154.2K
NURO On Other Exchanges
NURO is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

neurometrix inc (NURO) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/2/15 - $2.05
52 Week Low
07/24/15 - $0.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEUROMETRIX INC (NURO)

Related News

No related news articles were found.

neurometrix inc (NURO) Related Businessweek News

No Related Businessweek News Found

neurometrix inc (NURO) Details

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis, and diabetes. The company develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases, and sleep disorders. Its marketed products include Quell, a wearable device for relief of chronic pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic, intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons primarily in the United States, Europe, Asia, and the Middle East. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

32 Employees
Last Reported Date: 02/25/15
Founded in 1996

neurometrix inc (NURO) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $647.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $437.4K
Senior Vice President and General Manager of ...
Total Annual Compensation: $156.1K
Compensation as of Fiscal Year 2014.

neurometrix inc (NURO) Key Developments

NeuroMetrix Announces Agreement With Advantage Consumer Healthcare to Expand Quell™ Retail Distribution

NeuroMetrix Inc. announced an agreement with Advantage Consumer Healthcare to expand distribution of its Quell wearable pain relief technology into mass merchandisers, chain drug stores and other retail opportunities.

Neurometrix Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

NeuroMetrix Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss of $1,203,206 or $0.48 per basic and diluted share on revenues of $1,224,987 against net loss of $2,170,710 or $0.85 per basic and diluted share on revenues of $1,343,770 a year ago. Loss from operations was $3,339,402 compared to $2,619,343 a year ago. For the six months, the company reported net loss of $3,274,434 or $0.74 per basic and diluted share on revenues of $2,507,947 against net loss of $3,395,308 or $1.06 per basic and diluted share on revenues of $2,675,307 a year ago. Loss from operations was $6,598,021 compared to $4,359,577 a year ago.

NeuroMetrix, Inc. Receives Non-Compliance Notice From NASDAQ

On July 16, 2015, NeuroMetrix, Inc. received a notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the last 30 consecutive business days, the bid price for the company’s common stock had closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The notification letter states that pursuant to NASDAQ Listing Rule 5810(c)(3)(A) the company will be afforded 180 calendar days, or until January 12, 2016, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the company’s common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of ten consecutive business days. If the company does not regain compliance by January 12, 2016, NASDAQ may provide written notification to the company that the company’s common stock will be delisted. At that time, the company may appeal NASDAQ’s delisting determination to a NASDAQ Listing Qualifications Panel. Alternatively, the company may be eligible for an additional 180 day grace period if it satisfies all of the requirements, other than the minimum bid price requirement, for listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5505. The notification letter has no effect at this time on the listing of the company’s common stock on The NASDAQ Capital Market. The company intends to actively monitor the bid price for its common stock between now and January 12, 2016 while demonstrating progress with its newest product, Quell, which was commercially launched in June 2015. The company believes that this will improve investor confidence and increase the market valuation of its common stock.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NURO:US $0.92 USD +0.0301

NURO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natus Medical Inc $41.40 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation NURO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROMETRIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at